NeuroPace IncNPCEEarnings & Financial Report
NeuroPace Inc is a medical technology company focused on developing and commercializing innovative implantable neurostimulation systems to treat neurological disorders, primarily drug-resistant epilepsy. Its core RNS System delivers personalized responsive stimulation to reduce seizure frequency, serving patients across North America and select global markets via partnerships with healthcare providers.
NPCE Q4 FY2025 Key Financial Metrics
Revenue
$26.6M
Gross Profit
$20.6M
Operating Profit
$-1.8M
Net Profit
$-2.7M
Gross Margin
77.4%
Operating Margin
-6.6%
Net Margin
-10.3%
YoY Growth
23.9%
EPS
$-0.08
NeuroPace Inc Q4 FY2025 Financial Summary
NeuroPace Inc reported revenue of $26.6M (up 23.9% YoY) for Q4 FY2025, with a net profit of $-2.7M (up 48.0% YoY) (-10.3% margin). Cost of goods sold was $6.0M, operating expenses totaled $22.3M.
Key Financial Metrics
| Total Revenue | $26.6M |
|---|---|
| Net Profit | $-2.7M |
| Gross Margin | 77.4% |
| Operating Margin | -6.6% |
| Report Period | Q4 FY2025 |
NeuroPace Inc Annual Revenue by Year
NeuroPace Inc annual revenue history includes year-by-year totals (for example, 2025 revenue was $100.0M).
NeuroPace Inc Quarterly Revenue & Net Profit History
NeuroPace Inc results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $26.6M | +23.9% | $-2.7M | -10.3% |
| Q3 FY2025 | $27.4M | +29.9% | $-3.5M | -12.8% |
| Q2 FY2025 | $23.5M | +22.1% | $-8.7M | -36.8% |
| Q1 FY2025 | $22.5M | +24.3% | $-6.6M | -29.3% |
| Q4 FY2024 | $21.5M | +19.2% | $-5.3M | -24.5% |
| Q3 FY2024 | $21.1M | +28.2% | $-5.5M | -25.9% |
| Q2 FY2024 | $19.3M | +16.6% | $-7.5M | -39.0% |
| Q1 FY2024 | $18.1M | +25.2% | $-8.9M | -49.2% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $18.1M | $19.3M | $21.1M | $21.5M | $22.5M | $23.5M | $27.4M | $26.6M |
| YoY Growth | 25.2% | 16.6% | 28.2% | 19.2% | 24.3% | 22.1% | 29.9% | 23.9% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $98.9M | $94.4M | $96.3M | $94.6M | $110.2M | $106.1M | $107.3M | $105.6M |
| Liabilities | $84.5M | $84.5M | $86.5M | $86.6M | $85.9M | $86.7M | $88.7M | $86.5M |
| Equity | $14.3M | $9.9M | $9.8M | $8.0M | $24.3M | $19.4M | $18.5M | $19.0M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-7.5M | $-3.9M | $-1.7M | $-4.8M | $-7.5M | $-2.1M | $-1.9M | $506000 |